Completed
A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
NCT01652703
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hypercholesterolemia and High Risk for Cardiovascular Events, +4 more
- Locations
-
- Research Site Nagoya, Aichi-ken, Japan
- Research Site Nagoya, Aichi-ken, Japan
- Research Site Nagoya, Aichi-ken, Japan
- Research Site Fukui-shi, Fukui, Japan